Entrada Therapeutics, Inc.
TRDA
$11.88
-$0.71-5.64%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 1.30M | 1.61M | 1.95M | 20.56M | 37.40M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.30M | 1.61M | 1.95M | 20.56M | 37.40M |
| Cost of Revenue | 32.26M | 38.36M | 37.88M | 32.07M | 33.41M |
| Gross Profit | -30.96M | -36.75M | -35.93M | -11.52M | 3.99M |
| SG&A Expenses | 9.35M | 10.30M | 10.92M | 10.27M | 9.86M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 41.61M | 48.67M | 48.80M | 42.35M | 43.27M |
| Operating Income | -40.31M | -47.05M | -46.85M | -21.79M | -5.87M |
| Income Before Tax | -39.07M | -43.48M | -42.93M | -17.35M | -739.00K |
| Income Tax Expenses | 92.00K | 654.00K | 178.00K | -- | -1.87M |
| Earnings from Continuing Operations | -39.16M | -44.13M | -43.10M | -17.35M | 1.13M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -39.16M | -44.13M | -43.10M | -17.35M | 1.13M |
| EBIT | -40.31M | -47.05M | -46.85M | -21.79M | -5.87M |
| EBITDA | -39.42M | -45.82M | -45.82M | -20.84M | -4.88M |
| EPS Basic | -0.94 | -1.06 | -1.04 | -0.42 | 0.03 |
| Normalized Basic EPS | -0.56 | -0.66 | -0.65 | -0.26 | -0.01 |
| EPS Diluted | -0.94 | -1.06 | -1.04 | -0.42 | 0.02 |
| Normalized Diluted EPS | -0.56 | -0.66 | -0.65 | -0.26 | -0.01 |
| Average Basic Shares Outstanding | 41.60M | 41.46M | 41.34M | 41.07M | 40.84M |
| Average Diluted Shares Outstanding | 41.60M | 41.46M | 41.34M | 41.07M | 43.05M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |